Epidermal growth factor (EGF) prevents methylprednisolone-induced inhibition of wound healing.
Subcutaneously implanted cylindrical hollow viscose cellulose sponges were used to study the effect of locally applied epidermal growth factor (EGF) on methylprednisolone-induced inhibition of granulation tissue formation in rats. In in vivo studies the sponges were treated immediately after implantation with a single injection of 2 mg (approximately 1.7 x 10(-3) M) of depot methylprednisolone or with its carrier solution only. Thereafter the implants were injected daily with 5 micrograms of EGF or with its carrier solution 0.1% albumin for 7 days. Methylprednisolone treatment decreased the accumulation of nucleic acids, collagen, and glycosaminoglycans in the developing granulation tissue. After daily injections of EGF the concentrations of these tissue components returned close to the control values. In cultures of rat granulation tissue fibroblasts, 10(-4) M and 10(-3)M methylprednisolone decreased collagen synthesis by 41 and 81% from the control level, respectively. In the presence of methylprednisolone EGF treatment could not increase collagen synthesis of fibroblasts. Methylprednisolone treatment resulted in a dose-dependent reduction in pro alpha 1(I) collagen mRNA levels, which was partially inhibited by low EGF concentrations (1 and 10 ng/ml). In the presence of methylprednisolone all concentrations of EGF increased fibronectin mRNA levels in a dose-dependent manner. It is concluded that EGF treatment can prevent the inhibitory effect of methylprednisolone on wound healing by stimulating fibroblast proliferation but does not stimulate collagen synthesis per cell.
Laato
M
M
Department of Surgery and Medical Biochemistry, University of Turku, Finland.
Heino
J
J
Kähäri
V M
VM
Niinikoski
J
J
Gerdin
B
B
D000818:Animals; D003094:Collagen / Q000096:biosynthesis; D004247:DNA / Q000032:analysis; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D005353:Fibronectins / Q000235:genetics; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000235:genetics; D006595:Hexosamines / Q000032:analysis; D006909:Hydroxyproline / Q000032:analysis; D008297:Male; D008775:Methylprednisolone / Q000494:pharmacology*; D009504:Neutrophils / Q000166:cytology; D011347:Procollagen / Q000235:genetics; D019736:Prostheses and Implants; D012313:RNA / Q000032:analysis; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D011919:Rats, Inbred Strains; D014574:Uronic Acids / Q000032:analysis; D014945:Wound Healing / Q000187:drug effects*
D005353:Fibronectins; D006595:Hexosamines; D011347:Procollagen; D012333:RNA, Messenger; D014574:Uronic Acids; D004815:Epidermal Growth Factor; D012313:RNA; D003094:Collagen; D004247:DNA; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D006909:Hydroxyproline; D008775:Methylprednisolone